RE: 201 data25 Apr 2020 14:52
60p- to be clear your assumption ghat the compounds have no value is your opinion. It isn’t based on anything but a hunch of yours.
What is a fact is that the company released an RNS stating that
The results appear, in advance of full analysis, to indicate that the VAL201 compound has a clear impact on patients with prostate cancer, as measured by PSA - evidence that is supported from tumour imaging (MRI and CT) in subjects. The compound has also shown it is very safe and has a high degree of tolerability, up to a dose that is in excess of the predicted dose and any practical therapeutic concentration.